



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pathophysiology

ESPS manuscript NO: 20796

Title: Promising biological therapies for ulcerative colitis: A review of the literature

Journal Editor-in-Chief (Associate Editor): Thomas Y Ma

Country: United States

Editorial Director: Xiu-Xia Song

Date sent for review: 2015-10-14 17:28

Date reviewed: 2015-10-17 05:59

ACADEMIC CONTENT EVALUATION	LANGUAGE QUALITY EVALUATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Revision
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Rejection

JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

In this review manuscript, the authors review the use of biologics in the treatment of UC. It is well-written and covers the recently approved biologics for UC. There is an important flaw in the review that must be corrected. Although the authors mention various studies with different biologics, they omit or overlook a critical component of the studies. They do not discuss the outcome of the studies presented. This is a critical flaw and must be corrected before the manuscript can be considered for publication. The authors need to state the outcome of the studies mentioned with regards to infliximab, adalimumab, golimumab, etc....